MabVax Therapeutics Holdings, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 1,996 3,524 5,566 11,040
Sales, General and Admin. 3,245 4,455 6,491 14,590
Non-Recurring Items - - - 425
Other - - - -
Operating Income (5,241) (7,979) (12,057) (26,055)
Income From Continuing Operations
Add'l Income/Expense Items 11 8 35 1,339
Earnings Before Interest and Tax (5,230) (7,971) (12,022) (24,716)
Interest Expense - - - 6
Earnings Before Tax (5,230) (7,971) (12,022) (24,722)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (5,230) (7,971) (12,022) (24,722)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,230) (7,971) (12,022) (24,722)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (5,230) (7,971) (12,022) (24,722)